Review

Potency and Selectivity of SMAC/DIABLO Mimetics in Solid Tumor Therapy

Xiao-Yun Zhao †, Xiu-Yun Wang †, Qi-Yao Wei †, Yan-Ming Xu * and Andy T. Y. Lau *

Laboratory of Cancer Biology and Epigenetics, Department of Cell Biology and Genetics, Shantou University Medical College, Shantou 515041, China; 18xyzhaow@stu.edu.cn (X.-Y.Z.); 19xywang@stu.edu.cn (X.-Y.W.); 19qywei@stu.edu.cn (Q.-Y.W.)
* Correspondence: amyymxu@stu.edu.cn (Y.-M.X.); andytylau@stu.edu.cn (A.T.Y.L.);
† These authors contributed equally to this work.

Received: 9 February 2020; Accepted: 13 April 2020; Published: 18 April 2020

Abstract: Aiming to promote cancer cell apoptosis is a mainstream strategy of cancer therapy. The second mitochondria-derived activator of caspase (SMAC)/direct inhibitor of apoptosis protein (IAP)-binding protein with low pI (DIABLO) protein is an essential and endogenous antagonist of inhibitor of apoptosis proteins (IAPs). SMAC mimetics (SMs) are a series of synthetically chemical compounds. Via database analysis and literature searching, we summarize the potential mechanisms of endogenous SMAC inefficiency, degradation, mutation, releasing blockage, and depression. We review the development of SMs, as well as preclinical and clinical outcomes of SMs in solid tumor treatment, and we analyze their strengths, weaknesses, opportunities, and threats from our point of view. We also highlight several questions in need of further investigation.

Keywords: inhibitor of apoptosis protein (IAP); second mitochondria-derived activator of caspase (SMAC); direct IAP-binding protein with low pI (DIABLO); SMAC mimetics (SMs); clinical trial; therapy; solid tumor

1. Introduction

In cancer biology, resistance to cell death is one of the hallmarks of cancer. Programmed cell death (PCD), especially apoptosis, functions as a natural defense to cancer development [1]. Afterward, targeted drugs to promote PCD emerged, exemplified by apoptosis-inducing compounds, showing their potential in cancer therapy [2]. The inhibitor of apoptosis proteins (IAPs) are a class of apoptosis regulators, which present a crucial role in the control of cell survival by suppressing both initiator and effector caspases [3,4]. Second mitochondria-derived activator of caspase (SMAC) could promote caspase activation by binding to IAPs and removing the inhibition of IAPs to caspases [5]. Direct targeting of IAPs by using mimetics of its natural antagonist SMAC can synergize the effect of traditional cancer therapy in myeloid malignancies, e.g., acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) [6]. In this review, we focus on the application of SMAC mimetics (SMs) in solid tumor therapy. By analyzing the potential mechanism of endogenous SMAC inefficiency, summarizing the latest preclinical and clinical outcomes of SMs in solid tumor treatment, and updating the cell death pathways regulated by SMs, we wish to deliver insight into the further application of SMs in cancer therapy.
2. SMAC in Cancers

2.1. Reduced SMAC Expression/Promoted SMAC Degradation

Perturbation of apoptosis is a vital cause in carcinogenesis and tumor progression. In the process of apoptosis, SMAC plays an important part. SMAC was identified as a detergent-soluble factor, which can stimulate caspase-3 activation in the presence of the known water-soluble factors Apaf-1, cytochrome c, and procaspase-9 in 2000 [5]. After that, it was found to be identical to direct IAP-binding protein with low pi (DIABLO) according to their sequences in 2000 [7]. SMAC/DIABLO is ubiquitously expressed in normal tissues, and the expression of SMAC messenger RNA (mRNA) in adult testis is the highest [8].

According to previous research data, the expression of SMAC is altered in many malignant tumors compared with normal tissues. The expression of SMAC is downregulated in renal cell carcinoma [9,10], colorectal cancer [11], bladder cancer [12,13], lung cancer [14], hepatocellular carcinoma [15], and testicular germ cell tumors [16]. Heat-shock transcription factor 1 (HSF1) downregulates SMAC expression in pancreatic cancer cells, thus promoting pancreatic cancer [17]. On the other hand, SMAC is also overexpressed in some tumors. High SMAC expression is linked to early local recurrence of cervical cancer [18], and additional non-apoptotic functions of SMAC are related to regulating phospholipid synthesis essential for cancer growth and development [19]. In addition, SMAC can be upregulated by transcription factor E2F1 (E2F1) in lung cancer at both mRNA and protein levels [20]. As stated in the chart calculating the datasets from The Cancer Genome Atlas (TCGA) program, downloaded from UALCAN (a comprehensive, user-friendly, and interactive web resource for analyzing cancer omics data) [21], SMAC is generally upregulated in cancers at the mRNA level (Figure 1a).

![Figure 1. Cont.](image-url)
Figure 1. An overview of the expressions of second mitochondria-derived activator of caspase (SMAC)/direct inhibitor of apoptosis (IAP)-binding protein with low pI (DIABLO), apoptosis regulator BCL-2 (BCL-2) family members, baculoviral IAP repeat-containing protein 5 (survivin/BIRC5), IAPs, TNF-related apoptosis-inducing ligand (TRAIL), tumor necrosis factor (TNF), and ubiquitin-specific protease 11 (USP11) across The Cancer Genome Atlas (TCGA) cancers (with primary tumor and normal samples) from UALCAN (a comprehensive, user-friendly, and interactive web resource for analyzing cancer omics data). X-axis labeling is the category of cancer types. Y-axis is the logarithm of transcripts per million (TPM) of different samples. “TPM + 1” is used to avoid a situation where there is no solution when TPM is equal to zero. (a) SMAC is generally upregulated in the cancers listed. (b–d) The anti-apoptotic/pro-survival BCL-2 proteins, BCL2A1, BCL2L1, and BCL2 are significantly overexpressed in some types of tumors compared with normal tissues. (e) A pervasive high level of survivin in primary tumors. (f–h) High messenger RNA (mRNA) levels of IAPs in some types of cancer. (i–k) Increased TRAIL, TNFα, and decreased USP11 might be conducive to the effect of SMAC mimetics (SMs) on cancers (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).

For one thing, SMAC is a pro-apoptotic protein that counteracts the inhibitory activity of IAPs leading to activation of caspases and apoptosis [7,22,23]. SMAC was described as an inhibitor of XIAP in the beginning, binding to the baculoviral IAP repeat (BIR) domains, BIR 2 and BIR 3 [24]. Then, some researchers found that SMAC can selectively induce the degradation of cellular inhibitor of apoptosis 1 and 2 (cIAP1 and cIAP2) in HeLa cells, but not XIAP [25]. In other researches, SMAC3, a SMAC splicing variant, was shown to have the ability to induce auto-ubiquitination and destruction of XIAP [8]. Like many RING domain-containing proteins, XIAP, cIAP1, and cIAP2 possess ubiquitin ligase activity toward themselves and other target proteins [26–29]. Likewise, cIAP1 (BIR-containing protein 2, BIRC2) [30], cIAP2 (BIRC3) [30], XIAP (BIRC4) [26,31,32], Livin (KIAP/ML-IAP/BIRC7) [33], and Bruce (Apollon/BIRC6) [34] were demonstrated as ubiquitin-protein ligases for SMAC. These results show that IAPs can promote SMAC degradation via the ubiquitin-proteasome pathway.

Although SMAC is more likely to be upregulated than downregulated at the mRNA level in cancers, its pro-apoptotic ability might have a weak role because of degradation. As a result of either lower expression or higher degradation, the low level of SMAC could cause an increased apoptotic
threshold which would allow cancer cells to develop an enhanced resistance to novel clinical treatments aiming at inducing apoptosis. This is why a low level of SMAC is associated with shorter survival [10], resistance to therapies [12], or poorer prognosis [11,13,14].

2.2. Blockage of SMAC Release

SMAC could promote caspase activation by removing the inhibition of IAPs. Only mature SMAC has this activity, while its precursor with an intact signal sequence does not. At the N-terminus of SMAC, there is a stretch of amino acids characteristic of mitochondrial targeting sequences that are normally removed from SMAC upon import into mitochondria [5]. When released from mitochondria, SMAC acts as a targeted molecule.

Proteins of the apoptosis regulator BCL-2 (BCL-2) family control intrinsic/mitochondrial apoptotic pathway by regulating mitochondrial outer membrane permeabilization (MOMP) [35,36]. MOMP allows the release of mitochondrial proteins from the mitochondrial intermembrane space (IMS) into the cytosol, including cytochrome c, SMAC, and HtrA2/Omi [7,37–39]. Upon stimuli, effector proteins, such as apoptosis regulator BAX/BCL-2-like protein 4 (BAX), BCL-2 homologous antagonist/killer (BAK), and BCL-2-related ovarian killer protein (BOK), are activated and oligomerize at the mitochondria outer membrane to mediate MOMP [36,40,41]. The anti-apoptotic/pro-survival BCL-2 proteins, including apoptosis regulator BCL-2 (BCL2), BCL-2-like protein 1 (BCL2L1), BCL-2-like protein 2 (BCL2L2), induced myeloid leukemia cell differentiation protein MCL1 (MCL1), and BCL-2-related protein A1 (BCL2A1), suppress cell death by binding and inhibiting BAX and BAK [36]. The direct activator “BH3-only” proteins, BH3-interacting domain death agonist (BID) and BCL-2-like protein 11 (BIM), can directly induce BAK and BAX oligomerization and MOMP. The de-repressor “BH3-only” proteins, i.e., BCL-2-associated agonist of cell death (BAD), BCL-2-interacting killer (BIK), BCL-2-modifying factor (BMF), activator of apoptosis Harakiri (HRF), phorbol-12-myristate-13-acetate-induced protein 1 (Noxa), and BCL-2 binding component 3 (PUMA/BBC3), mainly interact with the anti-apoptotic proteins to promote apoptosis [42,43].

Although the BCL-2 family is involved in many diseases, the most distinguished one is cancer. The most potent and ubiquitous mechanism is overexpression of anti-apoptotic members [44]. From the chart downloaded from UALCAN [21] (Figure 1b–d), some anti-apoptotic BCL-2 proteins are visibly upregulated in some cancers. In this case, no matter whether the levels of BAX, BAK, and/or BOK are high or not, the MOMP-mediated release of SMAC would be relatively blocked.

Furthermore, there are other studies showing inhibitors of SMAC release. Survivin, another member of IAPs, can associate with SMAC in mitochondria to delay its release and stabilize the cytosolic levels of released SMAC in cytosol [45]. From the chart downloaded from UALCAN [21] (Figure 1e), baculoviral IAP repeat-containing protein 5 (survivin/BIRC5) is overexpressed in many cancers making it more possible to regulate the release of SMAC. This also supplements the interaction between SMAC and IAPs. In addition, heat-shock protein 27 (HSP27) can also inhibit the release of SMAC, thereby allowing increased survival and drug resistance in multiple myeloma (MM) cells [46].

2.3. Loss of IAP Binding Ability in Mutated SMAC

After SMAC is localized in the cytoplasm, its IAP-binding motif (IBM), which consists of four N-terminus amino-acid residues (Ala–Val–Pro–Ile), also known as the AVPI segment, interacts with BIR domains of IAPs [47–49]. SMAC dimerization is essential to its function in activating procaspase-3, promoting the enzymatic activity of mature caspase-3 [50], and relieving XIAP-mediated caspase inhibition [51]. It was proven that mutations of the first amino acid lead to loss of interaction with IAPs and concomitant loss of SMAC function [47,50], and that mutations of hydrophobic residues at the interface disrupt the dimer formation [50]. We can see that mutations of SMAC/DIABLO occurred in 95 samples out of 10,950 patients with cancer (0.9%) (Figure 2b) [52,53], this still might be a potential mechanism of SMAC dysfunction. It was shown that c-Jun N-terminal kinase 3 (JNK3) can phosphorylate...
SMAC. JNK3-mediated phosphorylation of SMAC markedly attenuates the interaction between SMAC and XIAP [54]. Thus, both mutations and phosphorylation might affect SMAC by changing its protein structure.

![Graph showing alteration frequency for various types of cancer](image_url)

**Figure 2.** (a) SMAC/DIABLO mutation analysis in various types of human cancers (cBioPortal). (b) Oncoprint in cBioPortal representing the proportion and distribution of samples with alterations in SMAC/DIABLO. Cancers without mutations and samples without alterations are not shown in the figure.

Furthermore, one study reported that functional mutation of SMAC underlies human progressive hearing loss, designated as autosomal-dominant nonsyndromic hearing loss 64 (DFNA64), by causing degradation of mutant and wild-type SMAC and leading to mitochondrial dysfunction [55].

### 2.4. Depression of SMAC Activity Due to Overexpression of IAPs

The pro-apoptotic activity of SMAC mainly acts on XIAP, cIAP1, and cIAP2. There is evidence to show that the average level of XIAP expression is higher in renal cell carcinoma compared to an autologous normal kidney [56], even increasing beyond that of SMAC [57]. IAPs are overexpressed in various solid and hematological malignancies, and high expression levels of IAPs are associated with resistance to standard chemotherapeutics and radiation therapy, as well as poor prognosis [4,58,59]. SMAC activity is depressed in the case of increased XIAP, cIAP1, or cIAP2. It is worse when other IAPs co-overexpress, as they compete with XIAP, cIAP1, or cIAP2 for binding to SMAC and, in this way, preserve them from inhibition by SMAC [60–62]. From the chart downloaded from UALCAN [21] (Figure 1f–h), we can also observe the overexpression of XIAP, cIAP1, and cIAP2 at the mRNA level in some types of cancer. Likewise, as mentioned above, IAPs can promote SMAC degradation through the ubiquitin-proteasome pathway.

In brief, as a result of either low level or dysfunction, the activity of SMAC decreases in cancer cells, rendering it unable to antagonize the upregulated IAPs. Thus, SMs, also known as IAP antagonists, which are a new class of targeted drugs to suppress the IAPs, came into view [63].
3. Mechanism of Action of SMs

SMs induce cancer cell death predominantly through a cIAP-dependent mechanism regulated by death receptor ligands, such as tumor necrosis factor alpha (TNFα) [64] (Figure 3). Binding of SMs to cIAP1 and cIAP2 leads to a conformational change of these IAP proteins, inducing its auto-ubiquitination and subsequent proteasomal-mediated degradation [65–67]. Degradation of cIAP1 and cIAP2 in cancer cells allows for the accumulation of nuclear factor-κB (NF-κB)-inducing kinase (NIK) and stimulates the activation of the non-canonical NF-κB pathway [67]. This stimulation of the NF-κB pathway causes an autocrine synthesis of cytotoxic cytokines like TNFα, which subsequently engages the TNF receptors such as TNF-R1 [68]. With depletion of cIAPs, TNFα cannot stimulate receptor-interacting protein 1 (RIP1) ubiquitination; subsequently, RIP1 that is released from the TNF-R1 complex assembles the death-inducing complex IIα, containing RIP1, tumor necrosis factor receptor superfamily member 6 (FAS)-associated protein with death domain (FADD), and caspase-8, which triggers caspase-8 activation and the TNFα-induced apoptotic pathway. This partly explains the combination of SMs with either chemo- or radiotherapy, which enhances the expression of TNFα, revealing synergistic activity [69]. Moreover, XIAP can also influence TNFα signaling, activate NF-κB, and block apoptosis at the effector phase, which is a point where multiple signaling pathways converge. Moreover, XIAP is a potent suppressor of TNF-related apoptosis-inducing ligand (TRAIL)/FasL-induced cell death by interacting with caspase-3, -7, or -9 [70,71]. Hence, treatments targeting XIAP may especially help to overcome resistance to chemotherapeutic agents. SMs directly bind XIAP, thereby activating caspases and inducing apoptosis of cancer cells [72]. Taken together, releasing caspases from the inhibitory interaction with IAP proteins and inducing apoptosis through extrinsic and intrinsic pathways can also provide a possible explanation for the phenomenon that the treatment of SMs sensitizes cancer cells to conventional chemo- and radiotherapy [73]. In other words, SMs, as sensitizers, reduce the threshold for cell death induced by chemo- or radiotherapy, which directly provoke cell death pathways. In situations in which a functional caspase-8 is deficient, SMs were reported to trigger the production of necrosome, consisting of RIP1, receptor-interacting protein kinase 3 (RIP3), and mixed lineage kinase domain-like (MLKL), thereby promoting cancer cells to undergo TNFα-stimulated necroptosis [74]. In the absence of functional caspase-8, the RIP1-containing complex IIα cannot be formed, allowing non-ubiquitinated RIP1 to interact with RIP3 through their RIP homotypic interaction motif [75]. Subsequently, activated RIP3 binds to and phosphorylates MLKL forming the necrosome, allowing necrotic cell death to take place.

Even though the vast majority of studies suggested that SM-facilitated cell death needs autocrine TNFα production, it was reported that SM-induced cell death also occurred in a TNFα-independent manner. The ripoptosome that contains RIP1, FADD, caspase-8, and cellular FADD-like interleukin beta-converting enzyme (FLICE)-like inhibitory protein (c-FLIP) can promote either apoptosis or necrosis [76,77]. c-FLIP is mainly expressed as two splice forms in human cells: a long form c-FLIPL and a short form c-FLIPS, and both of them exhibit their oncogenic function primarily by inhibiting caspase-8 activation [78]. Furthermore, the assembly of the ripoptosome is controlled, amongst others, by the two major isoforms of cFLIP. c-FLIPL prevents ripoptosome formation, but c-FLIPS promotes the assembly of ripoptosome [77]. When RIP1 level is low or cFLIPL level is high, cells are resistant to the formation of the ripoptosome, leading to death. Intriguingly, in the loss of cIAPs, c-FLIPS was able to protect cells from ripoptosome-induced apoptosis but evoked necroptosis, which is caused by the absence of caspase activity within the complex. In addition to their effect on the tumor cells, SM-induced loss of cIAP1/2 in immune cells can activate the alternative NF-κB pathway, which promotes B-cell survival and provides a broad co-stimulatory signal to dendritic cells and T cells [79]. These signals can further induce an immune-modulatory activity, resulting in the massive secretion of proinflammatory cytokines against cancer cells [80,81]. However, high-dose SM treatment may have side effects that can lead to systemic toxicity, to cytokine release syndrome, or to blunting of tumor responses to the death ligands.
In principle, SMs can kill cancer cells via multiple cell death pathways; thus, the anticancer effect of SMs is theoretically excellent. In fact, only a small subset of cancer cell lines tested to date appear to be effectively killed by single-agent SMs [82–84]. Lacking a mechanistic understanding of this resistance is a leading hurdle to the effective application of these drugs. Thus, a mass of work concentrated on the key mechanisms of therapeutic resistance to SMs in cancer cells. Previous studies confirmed that some cancer cells evade SM-induced cell death via stabilization of cIAP2 [85–87]. Some resistant cell lines have such an intense tendency to upregulate cIAP2, while sensitive cells seem to be less susceptible to signals that upregulate cIAP2. Accordingly, chemical inhibitors of phosphatidylinositol 3-kinase (PI3K) were confirmed to hamper cIAP2 upregulation and could, therefore, sensitize H1299 cells to cell death induced by SMs alone [83]. A recent study found that SM-induced degradation of cIAP2 relies on not only binding to tumor necrosis factor receptor-associated factor 2 (TRAF2), but also the presence of cIAP1 [66]. In the absence of cIAP1 or TRAF2, the newly generated cIAP2 is no longer downregulated by SMs. Another report showed that overexpression of ubiquitin-specific protease 11 (USP11) led to stabilization of cIAP2 and promoted SM therapeutic resistance [86].

**Figure 3.** Regulation of cell death pathways by SMs. The binding of SMs to cIAPs, which enhances the E3 ubiquitin ligase activity of cIAPs, resulting in autoubiquitination and proteasomal degradation. These alterations lead to nuclear factor-κB (NF-κB) accumulation, non-canonical NF-κB activation, and tumor necrosis factor alpha (TNFα) production. The degradation of cIAPs raises three possible formations, i.e., complex IIa, ripoptosome, and necrosome, which induce cancer cell death. Meanwhile, SMs can directly bind XIAP, thereby activating caspases and inducing apoptosis.

In addition, research showed that SM-induced loss of cIAP1/2, two critical regulators of the TNF receptor superfamily and NF-κB signaling, sensitizes cancer cells to TNFα- or TRAIL-mediated death [72]. Therefore, we suppose that a high level of TRAIL or TNF in cancer might make SMs more efficient. From the chart downloaded from UALCAN (Figure 1i–j), we can see that TRAIL and TNF do have high mRNA levels in a few types of cancer. On the other hand, studies showed that the deficiency of TNFα caused poor therapeutic efficacy of SMs [88,89]. According to recent research,
the cell surface protein leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) contributes resistance to SMs by upregulating receptor tyrosine kinase (RTK) signaling and attenuating TNFα expression [90]. Furthermore, the interferon regulatory factor 1 (IRF1) was investigated to be critical for inducing the production of SM-mediated TNFα [91]. Several recent studies showed that multiple cancer lines of different origins, including glioblastoma, melanoma, ovarian adenocarcinoma, pancreatic carcinoma, and breast cancer, were resistant to SM-induced death in the absence of the transcription factor specificity protein 3 (SP3), which promotes autocrine TNFα expression [92,93]. Based on the above, one can draw a conclusion that the presence of TNFα is pivotal in ensuring the excellent efficacy of SMs. Thus far, levels of TNFα would likely be a momentous desirable factor for pinpointing patients who will benefit from single-SM treatment.

However, high expression of TNFα is necessary but not sufficient for inducing apoptosis via this kind of treatment. In other words, many cancer cell lines are resistant to SM-mediated apoptosis with high expression of TNFα. Taking malignant pleural mesothelioma (MPM) as an example, even in MPM patients with high levels of TNFα, MPM cell lines assessed were exceedingly resistant to SMs either alone or when incubated in the presence of clinically relevant levels of TNFα [94]. Further studies revealed that SM sensitivity could be restored by downregulating c-FLIP, which is an enzymatically dead caspase-8 homolog preventing caspase-8-mediated apoptosis. Similar studies established that downregulating the anti-apoptotic protein c-FLIP is crucial for the susceptibility of breast cancer cell lines to SMs [95].

4. Development and Clinical Trials of SMs

4.1. Development of SMs

In general, SMs can be divided into monovalent and bivalent. Monovalent SMs are composed of one SMAC-mimicking unit, whereas bivalent or dimeric SMs comprise two units. Compared with the monovalent SMs, most of the existing bivalent SMs exhibit higher binding affinities, as well as an ability to bind to the BIR 2 and BIR 3 domains of XIAP, resulting in the simultaneous activation of caspase-3/7. Cong et al. focused on the research articles of the past 15 years and clearly summarized the structural interaction between IAPs and SMAC, four generations of SMs, and representative antagonists in clinical evaluations [96]. Subsequently, Zhu et al. showed detailed strategies for designing bivalent small-molecule SMs and the progress in using them to antagonize IAPs, as well as their clinical potential [97]. These latest summaries are enormously helpful to guide further study to optimize the properties of bivalent SMs to ensure good bioavailability and targeted accumulation in various types of tumors.

4.2. SMs in Therapies

In initial exploration, earlier studies showed that cell-permeable SMAC-based peptides as single agents could not induce apoptosis in tumor cells. However, they are capable of potentiating the anticancer activity of other agents [98–100]. In 2004, Oost and colleagues showed that SMAC peptide-mimetics inhibited cell growth in seven different cell lines with diverse tumor types by screening various cancer cell lines [101]. The bivalent SMs were initially shown to potentiate the activity of TRAIL and TNFα but had no activity as a single agent in the T98G glioma cell line [102]. In the subsequent studies, both monovalent and bivalent SMs were shown to be effective in inhibition of cell growth and induction of apoptosis in cancer cell lines [103–106]. These data with different SMs from a number of laboratories provided the evidence that SMs may have the potential for the treatment of human cancer, even when used as single agents.

4.2.1. Combined with Death-Inducing Ligands

As crucial antagonists of IAPs, SMs may effectively potentiate the antitumor activity of other anticancer agents. Earlier studies in 2002 showed that short SMAC peptides could synergize with the
TRAIL receptor to enhance apoptosis in various tumor cells and suppress tumor growth in vitro and in vivo [98–100]. TRAIL is a member of the TNFα family; however, unlike TNFα, TRAIL shows very low toxicity to normal cells and tissues and is well tolerated in clinical trials [107]. Similarly, TRAIL has minimal anticancer activity used as monotherapy in clinical trials, and this limited its clinical development. Hence, the combination of SMs with TRAIL seems to be a particularly attractive strategy. Indeed, the combination of SMs with TRAIL evinced synergistic activity in numerous investigations. It was found that the SMAC peptides strongly enhanced the antitumor activity of TRAIL in an intracranial malignant glioma xenograft model in vivo, and the combination achieved eradication of established tumors without detectable toxicity to normal brain tissue [98]. In 2004, a bivalent SM was highly effective in potentiating apoptosis when combined with TRAIL and TNFα but had no activity as a single agent in the T98G glioma cell line [102]. In later studies, SMs were also shown to enhance apoptosis induced by TRAIL in pancreatic carcinoma models in vitro and in vivo [108–110]. SMs were reported to decrease TRAIL-stimulated invasion and metastasis, even in cancers such as cholangiocarcinoma (CHOL) [111]. Moreover, it is highly synergistic with TRAIL in vitro in both TRAIL-sensitive and TRAIL-resistant cancer cell lines of breast, prostate, and colon cancer [112].

In addition to TRAIL, strong synergy was also observed between SMs and TNFα in various cancer cell lines, such as glioma, breast cancer, lung cancer, and so on [82,102,113]. A later study indicated that SMs can affect 48% of cell lines when combined with TNFα, which was found to be ineffective in induction of apoptosis of 51 different cancer cell lines [95]. In addition, birinapant, an SM, in combination with TNFα, was reported to inhibit the growth of melanoma, including the serine/threonine-protein kinase B-raf (BRAF) inhibitor-resistant cell line [114]. Earlier studies showed that, in apoptosis-resistant leukemia cells, SMs can potentiate TNF-induced necroptosis by enhancing the formation of the necrosome complex [84,115]. Subsequently, SM treatment induced massive cell death and led to regression of tumors in solid tumors [116,117]. These findings indicated that SMs can combine with death receptors to trigger apoptotic cell death.

4.2.2. Combined with Kinase Inhibitors

SMs were reported to potentiate the effects of epidermal growth factor receptor (EGFR, also known as ERBB1). For example, SMs targeting multiple IAPs promote apoptosis in response to the ERBB antagonists, trastuzumab, lapatinib, or gefitinib, in Her2-overexpressing breast cancer cells, or gefitinib in EGFR-overexpressing breast cancer cells [118]. Another study provided evidence that SMs display antitumor and anti-metastasis effects in vivo, and they contribute to EGFR inhibition and the reduction of its downstream mediators [119]. Furthermore, in glioblastoma, the SM LBW242 can synergize with several receptor tyrosine kinase inhibitors, including imatinib, nilotinib, nnp-aww541, and PKI166, to promote apoptosis [120]. Similarly, the simultaneous administration of SMs with bortezomib potently triggers apoptosis in a melanoma cell line [121].

4.2.3. Combined with Chemotherapy

SMs were shown to sensitize various cancers toward chemotherapy. Since the first preclinical evidence that SMs potentiate the effects of various chemotherapeutics, there are more and more studies on the synergistic anticancer effect of SMAC peptides and chemotherapeutic drugs. In 2002, there was a study demonstrating that the SMAC peptide can enhance the induction of apoptosis and long-term antiproliferative effects of diverse antineoplastic agents including paclitaxel, etoposide, 7-ethyl-10-hydroxycamptothecin (SN-38), and doxorubicin in breast cancer and immortalized cholangiocyte cell lines [99]. Further study demonstrated that a cell-permeable SMAC peptide selectively reversed the apoptotic resistance of H460 lung cancer cells and, in combination with taxol and cisplatin, regressed the tumor growth in vivo with little toxicity to the mice [100]. Subsequently, combination of the SM JP1201 with gemcitabine induced regression of tumors in orthotopic xenograft and syngeneic tumor models, and prolonged survival in xenograft and transgenic models of pancreatic
cancer [122]. A subsequent study also demonstrated this for synergistic sensitization of non-small-cell lung cancers to standard chemotherapy agents [123].

Series of SMs were proven to be able to enhance the antitumor effects in different cancer cell lines when combined with chemotherapy drugs in vitro. In 2011, it was demonstrated that a small-molecule SM, at nanomolar concentrations, significantly sensitized HNSC cells to gemcitabine-induced apoptosis and restored gemcitabine sensitivity in SMAC knockdown cells [124]. Then, LBW242 was found to strongly synergize with platin and taxol anticancer drugs that are commonly used in clinic in inducing apoptosis of ovarian cancer cells [125]. In 2017, it was reported that a synergistic combination of SM BV6 and bortezomib effectively triggers cell death in B-cell non-Hodgkin lymphoma cells, even when apoptosis is blocked [126]. In addition, the combination of birinapant with norcantharidin (NCTD) was reported to promote anticancer activity in breast cancer cells [127]. Of note, some SMs were reported to be able to reverse resistance to chemotherapy agents by inducing cell death depending on the cell lines. It was demonstrated that treatment of SM LCL161 not only increases the effects of vincristine in neuroblastoma cells, but it is also able to overcome vincristine resistance in neuroblastoma cells [128]. Subsequently, SM Debio 1143 in vitro was demonstrated to inhibit the cell viability of two carboplatin-sensitive cell lines (IGROV-1 and A2780S), as well as three carboplatin-resistant cell lines (A2780R, SKOV-3, and EFO-21) [129].

Significantly, SMs in combination with chemotherapy in different kinds of tumor models were also explored. In 2013, there was a study reporting that SM-164 in combination with gemcitabine increases the number of apoptotic and dead pancreatic cancer cells, as well as inhibits tumor xenograft growth in nude mice [130]. Then, patient-derived xenograft models showed that the activity of a variety of chemotherapeutic drugs is potentiated by birinapant, and tumor growth in multiple primary patient-derived xenograft models is inhibited by birinapant at well-tolerated doses [131]. In addition, a subsequent study showed that Debio 1143-containing combinations effectively inhibit the growth of lung adenocarcinoma both in vitro and in vivo [132]. In particular, a study showed that the combination of LCL161 with chemotherapy regimens such as rituximab, gemcitabine, or vinorelbine exhibits synergistic antitumor activity in models of resistant lymphoma both in vitro and in vivo, but not in rituximab-sensitive cell lines in vivo [133]. Similarly, results of a recent study showed that, in the osteosarcoma model, co-treatment with LCL161 and doxorubicin is particularly effective, impeding primary tumor growth and delaying or preventing metastasis; however, it only efficiently kills osteosarcoma cells when TNFα is supplied in vitro [134].

4.2.4. Combined with Radiotherapy

SMs were reported to enhance radiosensitivity in several types of cancer cell lines, such as colorectal cancer, glioblastoma, esophageal carcinoma (ESCA), and head and neck squamous cell carcinoma (HNSC). An early study showed that in vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by JP1201 decreased the survival of HT-29 cells and tumor growth via an additive effect in apoptosis, as well as a reduction in the level of XIAP and an impairment of DNA repair mechanisms [135]. Subsequently, another study reported that a SM compound, SM-164, can enhance the radiosensitization of HNSC via activation of caspases [136]. Similarly, LCL161 acts as a strong radiosensitizer in human ESCA cells by inhibiting the expression of cIAP1 and promoting the activation of caspase-8, leading to enhanced apoptosis [137]. BV6 was shown to stimulate NF-κB activation, which was required for the SM-conferred radiosensitization of glioblastoma cells [138]. In colorectal cancer cells, BV6 also sensitizes cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis [139]. Furthermore, a recent study showed that LCL161 preferentially radiosensitizes human papillomavirus-negative (HPV(−)) HNSC, providing justification for clinical testing of LCL161 in combination with radiation for patients with HPV(−) HNSC [140]. These studies demonstrated SMs as a promising strategy to counteract radiation resistance of cancer cells.

Nevertheless, there are a number of future challenges for the successful development of SMs as cancer therapeutics, as well as some drawbacks which emerged with the development of these
compounds resulting from the complex cellular functions. Here, we used Strengths, Weaknesses, Opportunities, and Threats (SWOT) analysis to evaluate SMs (Figure 4). SWOT analysis is a business strategic tool to assess both internal (strengths and weaknesses) and external (opportunities and threats) factors. It is used extensively in business settings to uncover new outlooks and identify problems that would impede progress. The synthesis of the clinically useful SMs can be achieved depending on reasonable strategic planning.

![SWOT Diagram](image)

**Figure 4.** The Strengths, Weaknesses, Opportunities, and Threats (SWOT) analysis of SMs from our point of view.

Collectively, the above preclinical trials provide strong evidence that SMs can enhance the anticancer activity of TNFα, TRAIL, and chemotherapeutic agents, as well as radiosensitization in diverse tumor types; these findings suggest the therapeutic potential of such combinations for the treatment of human cancer. Accordingly, most subsequent clinical trials embarked on the use of SMs in rationally designed combination regimens.

### 4.3. Clinical Trial Development of SMs in Solid Tumors

So far, many SMs were identified, and eight SMs were evaluated in early clinical trials as cancer therapeutics, as listed in Table 1, including five monovalent compounds (LCL161, Debio 1143/AT-406/SI-406, CUDC-427/GDC-0917, RG7419/GDC-0152, and ASTX660) and three bivalent agents (birinapant/TL32711, APG-1387/SI-1387, and AEG40826/HGS1029). Chemical structures of the SMs are summarized in Figure 5. They were investigated as either a single agent or in combination setting with an anticancer agent in both solid tumor and hematological malignancies in terms of safety characteristics, maximum tolerated dose, pharmacokinetics (PK), pharmacodynamics (PD), biomarker identification, and initial efficacy.

Among the clinical trials listed in Table 1, limited published data of the RG7419/GDC-0152 clinical efficacy exist; however, it was the first SM to enter a phase I trial in June 2007, and it had the best profile among a series of compounds in the study [141]. Although no toxicity or efficacy was reported in the phase I clinical trial for RG7419 (NCT00977067), when administered intravenously to patients with locally advanced or metastatic malignancies, GDC-0152 demonstrated linear PK over doses ranging from 0.049 to 1.48 mg/kg.

The first human phase I trial of CUDC-427/GDC-0917 (NCT01226277), a second-generation, orally bioavailable SM from Genentech, showed that CUDC-427/GDC-0917 can be administered safely at doses up to 600 mg daily for 14 days every three weeks. The absence of severe toxicity, the inhibition of cIAP1 in peripheral blood mononuclear cell, and the antitumor activity warrant further studies [142]. Before that, modeling and simulation techniques were applied to study the preclinical suitability of the drug, and the simulations of human GDC-0917 plasma concentration–time profile and cIAP1 degradation at the 5-mg starting dose in the phase I clinical trial agree well with the observations. This work shows the value of preclinical studies in the early stages of the drug development process [143].
**Table 1. SMs in completed or ongoing clinical trials.**

| Structural Class | SM Compound (Administration Route) | NCT Number | Phase | Status (As of 13 January 2020) | Cancer Type(s) | Drug(s) Combined | Trial Starting Date |
|------------------|------------------------------------|------------|-------|-------------------------------|----------------|-----------------|--------------------|
| LCL161 (oral)    | LCL161 (oral)                      | NCT0198838| I     | Completed                      | Advanced solid tumors | /               | November 2008     |
|                  |                                    | NCT01246055| I     | Completed                      | Solid tumors          | Paclitaxel      | April 2011        |
|                  |                                    | NCT01617668| II    | Completed                      | Breast cancer         | Paclitaxel      | August 2012       |
|                  |                                    | NCT01968915| I     | Completed                      | Advanced solid tumors | Paclitaxel      | November 2013     |
|                  |                                    | NCT01934634| I     | Unknown status                 | Metastatic pancreatic cancer | Gemcitabine and Nab-Paclitaxel | March 2014 |
|                  |                                    | NCT02649873| I/II | Active, not recruiting         | Small-cell lung cancer Ovarian cancer | Topotecan and pegylated granulocyte colony stimulating factor (PEG-GCSF) | 23 March 2016 |
|                  |                                    | NCT0289069 | I     | Recruiting                     | Colorectal cancer Non-small-cell lung carcinoma (adenocarcinoma) Triple-negative breast cancer Renal cell carcinoma | PDR001 | 14 October 2016 |
|                  |                                    | NCT01078649| I     | Completed                      | Cancer                | /               | 29 March 2010     |
|                  |                                    | NCT01930292| I     | Terminated                     | Lung cancer Ovarian cancer Breast cancer | Paclitaxel and carboplatin | April 2013 |
|                  |                                    | NCT02022098| Not Applicable | Active, not recruiting | Squamous cell carcinoma of the head and neck | Cisplatin and radiotherapy | October 2013 |
|                  |                                    | NCT03270176| I     | Recruiting                     | Non-small-cell lung carcinoma Neoplasms | Avelumab | 10 October 2017 |
|                  |                                    | NCT04122623| I/II | Recruiting                     | Solid tumors          | Nivolumab       | 8 April 2019      |
|                  |                                    | NCT03871959| I     | Recruiting                     | Adenocarcinoma of the pancreas Adenocarcinoma of the colon Adenocarcinoma of the rectum | Pembrolizumab | 13 September 2019 |
|                  |                                    | NCT01226277| II    | Completed                      | Solid tumors          | /               | October 2010      |
|                  |                                    | NCT00977067| I     | Terminated                     | Solid tumors          | /               | June 2007         |
| Monovalent       |                                    |            |       |                               |                      |                |                    |
| Debio 1143/AT-406/SM-406 (oral) | Debio 1143/AT-406/SM-406 (oral) | NCT02022098| Not Applicable | Active, not recruiting | Squamous cell carcinoma of the head and neck | Cisplatin and radiotherapy | October 2013 |
|                  |                                    | NCT03270176| I     | Recruiting                     | Non-small-cell lung carcinoma Neoplasms | Avelumab | 10 October 2017 |
|                  |                                    | NCT04122623| I/II | Recruiting                     | Solid tumors          | Nivolumab       | 8 April 2019      |
|                  |                                    | NCT03871959| I     | Recruiting                     | Adenocarcinoma of the pancreas Adenocarcinoma of the colon Adenocarcinoma of the rectum | Pembrolizumab | 13 September 2019 |
|                  |                                    | NCT01226277| II    | Completed                      | Solid tumors          | /               | October 2010      |
|                  |                                    | NCT00977067| I     | Terminated                     | Solid tumors          | /               | June 2007         |
|                  |                                    | NCT02503423| I/II | Recruiting                     | Solid tumors          | /               | July 2015         |
Table 1. Cont.

| Structural Class | SM Compound (Administration Route) | NCT Number     | Phase  | Status (As of 13 January 2020) | Cancer Type(s) | Drug(s) Combined | Trial Starting Date |
|------------------|----------------------------------|----------------|--------|-------------------------------|----------------|------------------|---------------------|
| Bivalent         | Birinapant/TL32711 (intravenous) | NCT00993239    | I      | Completed                      | Refractory solid tumors | /                | November 2009       |
|                  |                                  | NCT01188499    | I/II   | Completed                      | Advanced or metastatic solid tumors | Chemotherapy drugs | October 2010        |
|                  |                                  | NCT01573780    | I      | Terminated                     | Unspecified adult solid tumor    | Gemcitabine hydrochloride | April 2012          |
|                  |                                  | NCT01681368    | II     | Terminated                     | Epithelial ovarian cancer        | /                | 15 August 2012      |
|                  |                                  | NCT01766622    | II     | Withdraw                        | Ovarian neoplasms                | [18F]-CP18       | 30 November 2012    |
|                  |                                  | NCT01940172    | I      | Completed                      | Relapsed epithelial ovarian cancer | Conatumumab     | November 2013       |
|                  |                                  | NCT02597962    | I/II   | Recruiting                     | Solid tumors                     | Pembrolizumab    | 4 August 2017       |
|                  |                                  | NCT02756130    | I/II   | Withdraw                        | High-grade fallopian tube serous adenocarcinoma | Carboplatin | 1 August 2018       |
|                  |                                  | NCT03803774    | I      | Recruiting                     | Recurrent head and neck squamous cell carcinoma | Radiation: intensity-modulated radiation therapy | 7 January 2019     |
|                  |                                  | NCT03386526    | I/II   | Recruiting                     | Advanced solid tumors            | /                | 21 November 2017    |
|                  |                                  | NCT07078006    | I      | Completed                      | Solid tumors                     | /                | May 2008            |

Data were gathered by searching the National Institutes of Health (NIH)’s Clinical Trials.gov database at [https://clinicaltrials.gov/](https://clinicaltrials.gov/). This table includes information on clinical trials as of 13 January 2020.
Figure 5. Chemical structure of monovalent and bivalent SMs tested in completed or ongoing clinical trials as anticancer agents.

To date, seven studies which investigated the use of LCL161 as a solid tumor therapeutic were evaluated or are currently in the phase of early clinical trials. LCL161 was well tolerated on a weekly dosing schedule in 27 patients with advanced cancer (NCT01098838), and no dose-limiting toxicity was found at doses up to 1800 mg, administered as a single agent once weekly, in tablet formulation. This combined dose and formulation was well tolerated and had significant activity [144]. A total of 209 patients were enrolled in a randomized, phase II study of weekly paclitaxel with or without LCL161 (NCT01617668). The results indicated that the LCL161 with paclitaxel group showed higher pathological complete response rate (pCR) than the paclitaxel alone arm. Patients were randomized to the LCL161 1800 mg once weekly for 12 weeks; then, the LCL161 PK samples were taken on cycle 1 and cycle 4, where the median $T_{\text{max}}$ was about 3.72 h and 3.50 h, respectively, while the median area under the curve from the time of dosing to the last measurable concentration ($\text{AUC}_{\text{last}}$) was about 5250.70 ng·h/mL and 5522.58 ng·h/mL, respectively. In the overall study, more adverse events occurred in the combination arm compared to the paclitaxel alone arm, and pyrexia was the most common adverse event (19%) in the combination arm. In addition, two studies of LCL161 in combination with paclitaxel were completed, but no objective results were reported (NCT01968915 and NCT01240655). For the other studies, one is at the recruiting stage (NCT02890069), one is still active (NCT02649673), and one (NCT01934634) has an unknown status.

Debio 1143/AT-406/SM-406 is an oral agent currently being evaluated in six phase I or phase I/II trials on solid tumors [145]. The first trial (NCT01078649), a single-agent trial, was completed in 2014. Most common adverse drug reactions were fatigue (26%), nausea (23%), and vomiting (13%). One patient had a reversible elevation in aspartate transaminase (AST) which was the only
dose-limiting toxicity (DLT) observed, and the maximum tolerated dose (MTD) was not reached. PK was dose-proportional above 80 mg without evidence of drug accumulation. Debio 1143 was well tolerated at doses up to 900 mg and elicited PD effects at doses greater than 80 mg. Based on these preliminary results, it has the potential to be used as an adjunctive treatment [146]. Then, in 2013, two trials of Debio 1143 in combination with common therapies were initiated. One was a phase I trial of Debio 1143 in combination with both paclitaxel and carboplatin, which is terminated according to their last update, but there are no results posted currently (NCT01930292). In another trial (NCT02022098), Debio 1143 is currently being tested in a phase I/II randomized study to determine the MTD, safety, PK, and antitumor activity in combination with concurrent chemoradiation therapy. Subsequently, there was a phase I trial (NCT03270176) of a dose-finding study of Debio 1143 in combination with avelumab after platinum-based therapy, and the estimated completion of the trial is May 2022. Recently, two new clinical trials were initiated, and they are currently recruiting; one is a phase I/II trial (NCT04122625) to assess the safety and efficacy of Debio 1143 in combination with nivolumab, and the estimated completion is 20 January 2023. The other phase I trial (NCT03871959) of pembrolizumab in combination with Debio 1143 was mainly initiated to determine MTD, recommended phase II dose (RP2D), and recommended dosing regimen and to obtain target engagement data, and it is expected to be completed in May 2021.

Notably, the new monovalent non-peptidomimetic ASTX660 from Astex Pharmaceuticals [147], which showed the ability to induce apoptosis and the inhibition of tumor growth in a preclinical trial [64], is currently being tested in a phase I/II clinical trial (NCT02503423). It is a dose-escalation phase I/II study of advanced solid tumors and lymphomas. Although the phase II part of the study is ongoing, the ASTX660 demonstrated a manageable safety profile, and it showed the evidence of pharmacodynamic and preliminary clinical activity at the 180-mg/day RP2D [148].

Birinapant/TL32711 is a second-generation bivalent SM manufactured by TetraLogic Pharmaceuticals, and its tolerability was improved [149]. Birinapant/TL32711 was advanced into several phase I/II trial as a single agent (NCT00993239, NCT01486784, and NCT01681368). The first human phase I trial with birinapant as a single agent on dose escalation safety (NCT00993239) showed that birinapant was well tolerated with the MTD of 47 mg/m² with favorable PK/PD; however, at 63 mg/m², the dose-limiting toxicities included headache, nausea, and vomiting, and two cases of Bell’s palsy (grade 2) were observed [150]. These results support the ongoing clinical trials of birinapant in patients with cancer. In a phase II trial, the effectiveness of birinapant was evaluated (NCT01681368). Eleven patients received birinapant treatment alone, after which accrual was terminated for lack of clinical benefit as a single agent in this small population. Noonan and his teammate emphasized the importance of studying single-agent PD and activity of birinapant to design the rational combination therapy for future clinical trials [151]. To date, seven trials of the combination with birinapant/TL32711 in studies of solid tumor were advanced. Specifically, combinations with other standard chemotherapeutics such as irinotecan or docetaxel (NCT01188499) and conatumumab (NCT01940172) were completed, while combinations with gemcitabine (NCT01573780), pembrolizumab (NCT02587962) as well as intensity-modulated radiation therapy (NCT03803774) are in progress to identify optimal synergistic combinations. Among them, only one phase I/II trial (NCT01188499) posted results, which exhibited that birinapant does not show good results in safety and tolerability. In addition, two trials were withdrawn for unknown reasons (NCT01766622 and NCT02756130).

AEG40826/HGS1029, with an undisclosed structure (proposed to be a bivalent SM), was well tolerated in patients with advanced solid malignancies and intravenous schedules with an MTD of 3.2 mg/m² in a phase I trial (NCT00708006). HGS1029 induced rapid and sustained reduction of cIAP1 levels after a single dose of administration and showed evidence of apoptosis induction in patients [152]. Confirmed tumor regression was reported in a patient with colon cancer and two patients (NSCLC, adrenocortical cancer) had stable disease for more than six months. However, no further trials were reported.
Another bivalent SM APG-1387/SM-1387 developed by Ascentage Pharma company, which demonstrated a potent antitumor effect on nasopharyngeal carcinoma [153], was advanced into a phase I/II trial in patients with advanced solid tumors or hematologic malignancies to test the safety, tolerability, and PK and PD profile. The compound was used as a single agent or in combination with systemic anticancer agents (NCT03386526). To date, limited published data exist regarding the clinical efficacy of APG-1387/SM-1387 in solid tumors specifically.

Monovalent and bivalent SMs differ in their pharmacologic properties, as intravenous administration is necessary for bivalent compounds, whereas monovalent compounds are orally bioavailable. Many studies reported that bivalent SMs have a higher affinity than monovalent SMs, consequently providing them with a stronger antitumor activity [152,154]. However, it is not yet possible to compare the toxicity between monovalent and bivalent SMs, as well as their antitumor capacity in vivo, based on current clinical studies. So far, although various structurally optimized SMs were developed, researchers still need to investigate newer compounds in clinical trials.

5. Predicted Potential Markers of SM Precision Therapy

SMs entered clinical trials as a very promising anticancer therapy. However, cancer cell lines respond differentially to SMs, which makes the identification of predictive molecular markers for response to SMs necessary. As mentioned above, mechanistic studies revealed that expression of various factors such as caspase-8, TNFα, RIP1, c-FLIP, FADD, cIAP1/2, and XIAP is essential for SM-mediated tumor cell death. As studies demonstrated that SMs can also conduct TNFα-induced necroptosis, i.e., a caspase-independent cell death pathway, caspase activation might not be suitable for indicating SM activity. Similarly, TNFα, RIP1, c-FLIP, and FADD may serve important roles in contributing to SM resistance in tumor cell lines. Nevertheless, their expression levels cannot indicate SMs sensitivity, as SMs can induce tumor cells death through both TNFα-dependent and TNFα-independent pathways. Additionally, among these molecules, the level of anti-apoptotic proteins (e.g., cIAP1, cIAP2, and XIAP) is also not suited for predicting whether the treatment of SMs is effective or not. There are several reasons for this. Firstly, decreased expression levels of cIAP1 can be expected in non-tumor tissues, as well as sensitive and resistant malignancies. Secondly, as detailed above, SM treatment will be non-effective under conditions in which cIAP1 is absent and cIAP2 is expressed to high levels. Thirdly, cIAP2 initially degrades after treatment but rebounds and is refractory to subsequent degradation in cancer cells that cannot respond to SMs. Lastly, biomarkers predictive of response were analyzed in ovarian cancer, and it was found that cIAP1, XIAP, and caspase-9 are not positive markers indicating SM susceptibility [129].

cIAP2 itself is not a fitting biomarker of the SM treatment response. However, it is worth noting that cIAP2 knockdown, but not cIAP1 or XIAP knockdown, sensitized cancer cells to apoptotic cell death induced by SMs [83]. Moreover, cIAP1 expression levels are relatively high but are decreased more efficiently than cIAP2 with the treatment of SMs [66]. As cIAP2 degradation requires the presence of cIAP1, cIAP2 may become more stable when cIAP1 is depleted by SMs. Alternatively, elevated cIAP2 expression in certain cell lines renders resistance to SMs, suggesting that inactivation of cIAP2 may be a decisive factor in SM-induced cell death. Taken together, we speculate that regulators of cIAP2 (e.g., USP11) may serve as indicators of the expected efficacy of SMs. USP11 is a cIAP2-specific deubiquitylase, which selectively and specifically regulates cIAP2 stability independent of cIAP1 and XIAP. We utilized the UALCAN database to explore differences in the mRNA expression of USP11, between tumor and normal tissues in multiple cancers. As shown in Figure 1k, a total of 23 datasets were involved in the analysis. In total, 14 of 23 analyses revealed significant differences between cancer and normal groups.

Among them, overexpression of USP11 was found in CHOL, colon adenocarcinoma (COAD), HNSC, liver hepatocellular carcinoma (LIHC), and pheochromocytoma and paraganglioma (PCPG), while under-expression was observed in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), prostate adenocarcinoma (PRAD),
thyroid carcinoma (THCA), and uterine corpus endometrial carcinoma (UCEC). The protein expression levels of USP11 in cancers are yet to be analyzed through more experiments. However, the question as to whether or not levels of cIAP2-specific deubiquitylase may represent as suitable marker for patient selection also remains to be determined in future studies. In addition, the feedback upregulation of cIAP2 could be due to the loss of cIAP1-mediated ubiquitination, activation of NF-κB signaling by SMs, or alterations in other signaling pathways, such as the PI3K/protein kinase B-serine/threonine kinase (Akt) pathway, which regulate cIAP2 expression, whereby molecules in these pathways may also be helpful to judge the expected efficacy of SMs.

6. Conclusions

The main goal of the research and development of drugs is to provide life-saving clinical medication. This review highlighted several mechanisms of decreased expression of SMAC/DIABLO in tumors and situations where there will or will not be therapeutic responses to SMs. Meanwhile, we also showed clinical studies of SMs, which manifested an acceptable safety of their use as a single agent or together with conventional or nonconventional drugs. As SMs are either directly involved in cell death pathways or strengthened the sensitivity of cancer cells for additional cytotoxic stimuli, the ultimate outcome of the treatment is the result of a complicated network of different effects. Thus far, SMs are very promisingly molecular targeted anticancer drugs, which have wide-ranging applications. However, there is still a long way to maximize the effectiveness of SMs in clinical therapy, such as minimizing its potential side effects, determining fitting predictive biomarkers, and drug combinations in individual cancers. A related consideration in the clinical development of SMs surrounds the consequences of its induction of NF-κB activation, whose possible adverse effects include increased levels of cytokines in normal tissues [155]. Researches showed that cytokine release syndrome was found to be dose-related and occurred at higher doses of SMs. Thus, work needs to be done to establish the optimal dosage. For the better development of SMs as therapeutic agents, experimental investigations are also needed to validate suitable indications of SM effectiveness as monotherapies. Thus far, patients that will likely respond to SM treatment are yet to be identified. In summary, there is no doubt of the enormous therapeutic potential of SMs in combination with death-inducing ligands, kinase inhibitors, chemotherapy, and radiotherapy. The ongoing development of novel SMs with stronger potency and selectivity is tempting to maximize their antitumor activity.

Author Contributions: Writing—original draft preparation, X.-Y.Z., X.-Y.W., Q.-Y.W., Y.-M.X., and A.T.Y.L.; writing—review and editing, X.-Y.Z., X.-Y.W., Q.-Y.W., Y.-M.X., and A.T.Y.L.; supervision, Y.-M.X. and A.T.Y.L.; funding acquisition, Y.-M.X. and A.T.Y.L. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the grants from the National Natural Science Foundation of China (Nos. 31771582 and 31271445), the Guangdong Natural Science Foundation of China (No. 2017A030313131), the “Thousand, Hundred, and Ten” project of the Department of Education of Guangdong Province of China, the Basic and Applied Research Major Projects of Guangdong Province of China (2017KZDXM035 and 2018KZDXM036), and the “Yang Fan” Project of Guangdong Province of China ( Andy T. Y. Lau-2016; Yan-Ming Xu-2015).

Acknowledgments: We would like to thank members of the Lau and Xu laboratory for critical reading of this manuscript.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef] [PubMed]
2. Ke, B.; Tian, M.; Li, J.; Liu, B.; He, G. Targeting programmed cell death using small-molecule compounds to improve potential cancer therapy. Med. Res. Ret. 2016, 36, 983–1035. [CrossRef]
3. Fulda, S. Molecular pathways: Targeting inhibitor of apoptosis proteins in cancer—from molecular mechanism to therapeutic application. Clin. Cancer Res. 2014, 20, 289–295. [CrossRef]
4. Mohamed, M.S.; Bishr, M.K.; Almutairi, F.M.; Ali, A.G. Inhibitors of apoptosis: Clinical implications in cancer. *Apoptosis* **2017**, 22, 1487–1509. [CrossRef]

5. Du, C.; Fang, M.; Li, Y.; Li, L.; Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell* **2000**, 102, 33–42. [CrossRef]

6. Boddu, P.; Carter, B.Z.; Verstovsek, S.; Pemmaraju, N. SMAC mimetics as potential cancer therapeutics in myeloid malignancies. *Br. J. Haematol.* **2019**, 185, 219–231. [CrossRef]

7. Verhagen, A.M.; Ekert, P.G.; Fukushi, M.; Silke, J.; Connolly, L.M.; Reid, G.E.; Moritz, R.L.; Simpson, R.J.; Vaux, D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell* **2000**, 102, 43–53. [CrossRef]

8. Fu, J.; Jin, Y.; Arend, L.J. Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of X-linked inhibitor of apoptosis protein. *J. Biol. Chem.* **2003**, 278, 52660–52672. [CrossRef]

9. Mizutani, Y.; Nakanishi, H.; Yamamoto, K.; Li, Y.N.; Matsubara, H.; Mikami, K.; Okihara, K.; Kawauchi, A.; Bonavida, B.; Miki, T. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. *J. Clin. Oncol.* **2005**, 23, 448–454. [CrossRef] [PubMed]

10. Kempkensteffen, C.; Hinz, S.; Christoph, F.; Krause, H.; Magheli, A.; Schrader, M.; Schostak, M.; Miller, K.; Weikert, S. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. *J. Cancer Res. Clin. Oncol.* **2008**, 134, 543–550. [CrossRef] [PubMed]

11. Endo, K.; Kohnoe, S.; Watanabe, A.; Tashiro, H.; Sakata, H.; Morita, M.; Kakeji, Y.; Maehara, Y. Clinical significance of Smac/DIABLO expression in colorectal cancer. *Oncol. Rep.* **2009**, 21, 351–355. [CrossRef] [PubMed]

12. Mizutani, Y.; Katsuoka, Y.; Bonavida, B. Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy. *Int. J. Oncol.* **2010**, 37, 503–508. [CrossRef] [PubMed]

13. Mizutani, Y.; Katsuoka, Y.; Bonavida, B. Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer. *Int. J. Oncol.* **2012**, 40, 1246–1250. [CrossRef]

14. Sekimura, A.; Konishi, A.; Mizuno, K.; Kobayashi, Y.; Sasaki, H.; Yano, M.; Fukai, I.; Fujii, Y. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. *Oncol. Rep.* **2004**, 11, 797–802. [CrossRef]

15. Bao, S.T.; Gui, S.Q.; Lin, M.S. Relationship between expression of Smac and Survivin and apoptosis of primary hepatocellular carcinoma. *Hepatobiliary Pancreat. Dis. Int.* **2006**, 5, 580–583.

16. Kempkensteffen, C.; Jager, T.; Bub, J.; Weikert, S.; Hinz, S.; Christoph, F.; Krause, H.; Schostak, M.; Miller, K.; Schrader, M. The equilibrium of XIAP and Smac/DIABLO expression is gradually deranged during the development and progression of testicular germ cell tumours. *Int. J. Androl.* **2007**, 30, 476–483. [CrossRef]

17. Liang, W.; Liao, Y.; Zhang, J.; Huang, Q.; Luo, W.; Yu, J.; Gong, J.; Zhou, Y.; Li, X.; Tang, B.; et al. Heat shock factor 1 inhibits the mitochondrial apoptosis pathway by regulating second mitochondria-derived activator of caspase to promote pancreatic tumorigenesis. *J. Exp. Clin. Cancer Res.* **2017**, 36, 64. [CrossRef]

18. Arellano-Llamas, A.; Garcia, F.J.; Perez, D.; Cantu, D.; Espinosa, M.; De la Garza, J.G.; Maldonado, V.; Melendez-Zaigla, J. High Smac/DIABLO expression is associated with early local recurrence of cervical cancer. *BMC Cancer* **2006**, 6, 256. [CrossRef]

19. Paul, A.; Krelin, Y.; Arif, T.; Jeger, R.; Shoshan-Barmatz, V. A new role for the mitochondrial pro-apoptotic protein SMAC/Diablo in phospholipid synthesis associated with tumorigenesis. *Mol. Ther.* **2018**, 26, 680–694. [CrossRef]

20. Xie, W.; Jiang, P.; Miao, L.; Zhao, Y.; Zhimin, Z.; Qing, L.; Zhu, W.G.; Wu, M. Novel link between E2F1 and Smac/DIABLO: Proapoptotic Smac/DIABLO is transcriptionally upregulated by E2F1. *Nucleic Acids Res.* **2006**, 34, 2046–2055. [CrossRef]

21. Chandrashekar, D.S.; Bashel, B.; Balasubramanyam, S.A.H.; Creighton, C.J.; Ponce-Rodriguez, I.; Chakravarti, B.; Varambally, S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. *Neoplasia* **2017**, 19, 649–658. [CrossRef] [PubMed]

22. Kominsky, D.J.; Bickel, R.J.; Tyler, K.L. Reovirus-induced apoptosis requires mitochondrial release of Smac/DIABLO and involves reduction of cellular inhibitor of apoptosis protein levels. *J. Virol.* **2002**, 76, 11414–11424. [CrossRef]
23. Wilkinson, J.C.; Wilkinson, A.S.; Scott, F.L.; Csomos, R.A.; Salvesen, G.S.; Duckett, C.S. Neutralization of Smac/Diablo by inhibitors of apoptosis (IAPs). A caspase-independent mechanism for apoptotic inhibition. *J. Biol. Chem.* 2004, 279, S1082–S1090. [CrossRef] [PubMed]

24. Suzuki, Y.; Imai, Y.; Nakayama, H.; Takahashi, K.; Takio, K.; Takahashi, R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. *Mol. Cell* 2001, 8, 613–621. [CrossRef]

25. Yang, Q.H.; Du, C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. *J. Biol. Chem.* 2004, 279, 16963–16970. [CrossRef]

26. Yang, Y.; Fang, S.; Jensen, J.P.; Weissman, A.M.; Ashwell, J.D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. *Science* 2000, 288, 874–877. [CrossRef]

27. Huang, H.; Joazeiro, C.A.; Bonfoco, E.; Kamada, S.; Levenson, J.D.; Hunter, T. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. *J. Biol. Chem.* 2000, 275, 26661–26664. [CrossRef]

28. Suzuki, Y.; Nakabayashi, Y.; Takahashi, R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. *Proc. Natl. Acad. Sci. USA* 2001, 98, 8662–8667. [CrossRef]

29. Li, X.; Yang, Y.; Ashwell, J.D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. *Nature* 2002, 416, 345–347. [CrossRef]

30. Hu, S.; Yang, X. Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. *J. Biol. Chem.* 2003, 278, 10055–10060. [CrossRef]

31. MacFarlane, M.; Merrison, W.; Bratton, S.B.; Cohen, G.M. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. *J. Biol. Chem.* 2002, 277, 36611–36616. [CrossRef] [PubMed]

32. Morizane, Y.; Honda, R.; Fukami, K.; Yasuda, H. X-linked inhibitor of apoptosis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/DIABLO. *J. Biochem.* 2005, 137, 125–132. [CrossRef] [PubMed]

33. Ma, L.; Huang, Y.; Song, Z.; Feng, S.; Tian, X.; Du, W.; Qiu, X.; Heese, K.; Wu, M. Livin promotes Smac/DIABLO degradation by ubiquitin-proteasome pathway. *Cell Death Differ.* 2006, 13, 2079–2088. [CrossRef]

34. Hao, Y.; Sekine, K.; Kawabata, A.; Nakamura, H.; Ishioka, T.; Ohata, H.; Katayama, R.; Hashimoto, C.; Zhang, X.; Noda, T.; et al. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. *Nat. Cell Biol.* 2004, 6, 849–860. [CrossRef]

35. Adams, J.M.; Cory, S. The Bcl-2 protein family: Arbiters of cell survival. *Science* 1998, 281, 1322–1326. [CrossRef]

36. Peña-Blanco, A.; García-Sáez, A.J. Bak, Bak and beyond - mitochondrial performance in apoptosis. *FEBS J.* 2018, 285, 416–431. [CrossRef]

37. Arnoult, D.; Gaume, B.; Karbowski, M.; Sharpe, J.C.; Cecconi, F.; Youle, R.J. Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. *EMBO J.* 2003, 22, 4385–4399. [CrossRef]

38. Wajant, H. Death receptors. *Eur. J. Cell Biol.* 2004, 83, 521–536. [CrossRef]

39. Tait, S.W.; Green, D.R. Mitochondria and cell death: Outer membrane permeabilization and beyond. *Nat. Rev. Mol. Cell Biol.* 2010, 11, 621–632. [CrossRef]

40. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy. *Nat. Rev. Drug Discov.* 2010, 9, 447–464. [CrossRef]

41. Llambi, F.; Wang, Y.M.; Victor, B.; Yang, M.; Schneider, D.M.; Gingras, S.; Parsons, M.J.; Zheng, J.H.; Brown, S.A.; Pelletier, S.; et al. BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-associated degradation. *Cell* 2016, 165, 421–433. [CrossRef] [PubMed]

42. Yu, J.; Wang, P.; Ming, L.; Wood, M.A.; Zhang, L. SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. *Oncogene* 2007, 26, 4189–4198. [CrossRef] [PubMed]

43. Chipuk, J.E.; Moldoveanu, T.; Llambi, F.; Parsons, M.J.; Green, D.R. The BCL-2 family reunion. *Nat. Rev. Mol. Cell Biol.* 2010, 11, 299–310. [CrossRef] [PubMed]

44. Letai, A.G. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. *Nat. Rev. Cancer* 2008, 8, 121–132. [CrossRef]

45. Ceballos-Cancino, G.; Espinosa, M.; Maldonado, V.; Melendez-Zajgla, J. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. *Oncogene* 2007, 26, 7569–7575. [CrossRef]
Chauhan, D.; Li, G.; Hideshima, T.; Podar, K.; Mitsiades, C.; Mitsiades, N.; Catley, L.; Tai, Y.T.; Hayashi, T.; Shringarpure, R.; et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. *Blood* 2003, 102, 3379–3386. [CrossRef]

Dohi, T.; Chai, J.; Suber, T.L.; Wu, J.W.; Du, C.; Wang, X.; Shi, Y. Structural basis of IAP recognition by Smac/DIABLO. *Nature* 2000, 408, 1008–1012. [CrossRef]

Srinivasula, S.M.; Ashwell, J.D. IAPs: What’s in a name? *Mol. Cell* 2008, 30, 123–135. [CrossRef]

Victoria-Acosta, G.; Martinez-Archundia, M.; Moreno-Vargas, L.; Melendez-Zajgla, J.; Martinez-Ruiz, G.U. Is there something else besides the proapoptotic AVPI-segment in the Smac/DIABLO protein? *Bol. Med. Hosp. Infant. Mex.* 2016, 73, 365–371. [CrossRef]

Chai, J.; Du, C.; Wu, J.W.; Kyin, S.; Wang, X.; Shi, Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. *Nature* 2000, 406, 855–862. [CrossRef]

Huang, Y.; Rich, R.L.; Myszka, D.G.; Wu, H. Requirement of both the second and third BIR domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac. *J. Biol. Chem.* 2003, 278, 49517–49522. [CrossRef] [PubMed]

Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012, 2, 401–404. [CrossRef] [PubMed]

Cheng, J.; Zhu, Y.; He, S.; Lu, Y.; Chen, J.; Han, B.; Petrillo, M.; Wrzeszczynski, K.O.; Yang, S.; Dai, P.; et al. Functional mutation of SMAC/DIABLO, encoding a mitochondrial proapoptotic protein, causes human progressive hearing loss DFNA64. *Am. J. Hum. Genet.* 2011, 89, 56–66. [CrossRef] [PubMed]

Mizutani, Y.; Nakanishi, H.; Li, Y.N.; Matsubara, H.; Yamamoto, K.; Sato, N.; Shiraishi, T.; Nakamura, T.; Mikami, K.; Okihara, K.; et al. Overyexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. *Int. J. Oncol.* 2007, 30, 919–925. [CrossRef] [PubMed]

Yan, Y.; Mahotka, C.; Heikaus, S.; Shibata, T.; Wethkamp, N.; Liebmann, J.; Suschek, C.V.; Guo, Y.; Gabbert, H.E.; Gerharz, C.D.; et al. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. *Br. J. Cancer* 2004, 91, 1349–1357. [CrossRef]

Nachmius, B.; Ashhab, Y.; Ben-Yehuda, D. The inhibitor of apoptosis protein family (IAPs): An emerging therapeutic target in cancer. *Semin. Cancer Biol.* 2004, 14, 231–243. [CrossRef]

Fulda, S. Inhibitor of apoptosis proteins as targets for anticancer therapy. *Exp. Rev. Anticancer Ther.* 2007, 7, 1255–1264. [CrossRef]

Dohi, T.; Okada, K.; Xia, F.; Wilford, C.E.; Samuel, T.; Welsh, K.; Marusawa, H.; Zou, H.; Armstrong, R.; Matsuzawa, S.; et al. An IAP-IAP complex inhibits apoptosis. *J. Biol. Chem.* 2004, 279, 34087–34090. [CrossRef] [PubMed]

McNeish, I.A.; Lopes, R.; Bell, S.J.; McKay, T.R.; Fernandez, M.; Lockley, M.; Wheatley, S.P.; Lemoine, N.R. Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. *Exp. Cell Res.* 2005, 302, 69–82. [CrossRef] [PubMed]

Dohi, T.; Xia, F.; Altieri, D.C. Compartementalized phosphorylation of IAP by protein kinase A regulates cytoprotection. *Mol. Cell* 2007, 27, 17–28. [CrossRef] [PubMed]

Ali, R.; Singh, S.; Haq, W. IAP proteins antagonist: An introduction and chemistry of Smac mimetics under clinical development. *Curr. Med. Chem.* 2018, 25, 3768–3795. [CrossRef] [PubMed]

Ward, G.A.; Lewis, E.J.; Ahn, J.S.; Johnson, C.N.; Lyons, J.F.; Martins, V.; Munck, J.M.; Rich, S.J.; Smyth, T.; Thompson, N.T.; et al. ASTX660, a novel non-peptidomimetic antagonist of cIAP1/2 and XIAP, potently induces TNFa/alpha-dependent apoptosis in cancer cell lines and inhibits tumor growth. *Mol. Cancer Ther.* 2018, 17, 1381–1391. [CrossRef]

Feltlham, R.; Bettjeman, B.; Budhidarmo, R.; Mace, P.D.; Shirley, S.; Condon, S.M.; Chunduru, S.K.; McKinlay, M.A.; Vaux, D.L.; Silke, J.; et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. *J. Biol. Chem.* 2011, 286, 17015–17028. [CrossRef]
66. Darding, M.; Feltham, R.; Tenev, T.; Bianchi, K.; Benetatos, C.; Silke, J.; Meier, P. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. *Cell Death Differ.* **2011**, *18*, 1376–1386. [CrossRef]

67. Varfolomeev, E.; Blankenship, J.W.; Wayson, S.M.; Fedorova, A.V.; Kayagaki, N.; Garg, P.; Zobel, K.; Dynek, J.N.; Elliott, L.O.; Wallweber, H.J.A.; et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. *Cell* **2007**, *131*, 669–681. [CrossRef]

68. Vince, J.E.; Wong, W.W.; Khan, N.; Feltham, R.; Chau, D.; Ahmed, A.U.; Benetatos, C.A.; Chunodru, S.K.; Condon, S.M.; McKinlay, M.; et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. *Cell* **2007**, *131*, 682–693. [CrossRef]

69. Hallahan, D.E.; Spriggs, D.R.; Beckett, M.A.; Kufe, D.W.; Weichselbaum, R.R. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. *Proc. Natl. Acad. Sci. USA* **1989**, *86*, 10104–10107. [CrossRef]

70. Finlay, D.; Vamos, M.; Gonzalez-Lopez, M.; Ardecky, R.J.; Ganji, S.R.; Yuan, H.; Su, Y.; Cooley, T.R.; Hauser, C.T.; Welsh, K.; et al. Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: Roles of XIAP and cIAPs. *Mol. Cancer Ther.* **2014**, *13*, 5–15. [CrossRef]

71. Brands, R.C.; Herbst, F.; Hartmann, S.; Seher, A.; Linz, C.; Kubler, A.C.; Muller-Richter, U.D.A. Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines. *Clin. Oral Investig.* **2016**, *20*, 2325–2332. [CrossRef] [PubMed]

72. Fulda, S.; Vucic, D. Targeting IAP proteins for therapeutic intervention in cancer. *Nat. Rev. Drug Discov.* **2012**, *11*, 109–124. [CrossRef] [PubMed]

73. Hill, R.P.; Zaidi, A.; Mahmood, J.; Jelveh, S. Investigations into the role of inflammation in normal tissue response to irradiation. *Radiat. Oncol.* **2011**, *101*, 73–79. [CrossRef] [PubMed]

74. Silke, J.; Rickard, J.A.; Gerlic, M. The diverse role of RIP kinases in necroptosis and inflammation. *Nat. Immunol.* **2015**, *16*, 689–697. [CrossRef]

75. Zhao, J.; Jitkaew, S.; Cai, Z.; Choksi, S.; Li, Q.; Luo, J.; Liu, Z.-G. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necroptosis. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 5322–5327. [CrossRef] [PubMed]

76. Tenev, T.; Bianchi, K.; Darding, M.; Broemer, M.; Langlais, C.; Wallberg, F.; Zachariou, A.; Lopez, J.; MacFarlane, M.; Cain, K.; et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. *Mol. Cell* **2011**, *43*, 432–448. [CrossRef]

77. Feoktistova, M.; Geserick, P.; Kellett, B.; Dimitrova, D.P.; Langlais, C.; Hupe, M.; Cain, K.; MacFarlane, M.; Häcker, G.; Levelkens, M. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. *Mol. Cell* **2011**, *43*, 449–463. [CrossRef]

78. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steinier, V.; Bodmer, J.L.; Schröter, M.; Burns, K.; Mattmann, C.; et al. Inhibition of death receptor signals by cellular FLIP. *Nature* **1997**, *388*, 190–195. [CrossRef]

79. Dougan, S.K.; Dougan, M. Regulation of innate and adaptive antitumor immunity by IAP antagonists. *Immunotherapy* **2018**, *10*, 787–796. [CrossRef]

80. Mo, X.; Tang, C.; Niu, Q.; Ma, T.; Du, Y.; Fu, H. HTiP: High-throughput immunomodulator phenotypic screening platform to reveal IAP antagonists as anti-cancer immune enhancers. *Cell Chem. Biol.* **2019**, *26*, 331–339.e3. [CrossRef]

81. Beug, S.T.; Tang, V.A.; LaCasse, E.C.; Cheung, H.H.; Beauregard, C.E.; Brun, J.; Nuyens, J.P.; Earl, N.; St-Jean, M.; Holbrook, J.; et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. *Nat. Biotechnol.* **2014**, *32*, 182–190. [CrossRef]

82. Petersen, S.L.; Wang, L.; Yalcin-Chin, A.; Li, L.; Peyton, M.; Minna, J.; Harran, P.; Wang, X. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. *Cancer Cell* **2007**, *12*, 445–456. [CrossRef] [PubMed]

83. Petersen, S.L.; Peyton, M.; Minna, J.D.; Wang, X. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 11936–11941. [CrossRef] [PubMed]

84. Laukens, B.; Jennewein, C.; Schenk, B.; Vanlangenakker, N.; Schier, A.; Cristofanon, S.; Zobel, K.; Deshayes, K.; Vucic, D.; Jeremias, I.; et al. Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. *Neoplasia* **2011**, *13*, 971–979. [CrossRef]

85. Lee, E.W.; Song, J. USP11: A key regulator of cIAP2 stability and sensitivity to SMAC mimetics. *Mol. Cell Oncol.* **2016**, *3*, e1029829. [CrossRef] [PubMed]
86. Lee, E.W.; Seong, D.; Seo, J.; Jeong, M.; Lee, H.K.; Song, J. USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics. *Cell Death Differ.* 2015, 22, 1463–1476. [CrossRef]

87. Ramakrishnan, V.; Painuliy, U.; Kimlinger, T.; Haug, J.; Rajkumar, S.V.; Kumar, S. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. *Leukemia* 2014, 28, 1519–1528. [CrossRef]

88. Bittner, S.; Knoll, G.; Ehrenschwender, M. Hyperosmotic stress enhances cytotoxicity of SMAC mimetics. *Cell Death Dis.* 2017, 8, e2967. [CrossRef]

89. Cornmark, L.; Larsson, C. New light on Smac mimetics and breast cancer. *Cell Death Dis.* 2016, 7, e2178. [CrossRef]

90. Bai, L.; McEachern, D.; Yang, C.Y.; Lu, J.; Sun, H.; Wang, S. LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNF-alpha expression and receptor tyrosine kinase signaling. *Cancer Res.* 2012, 72, 1229–1238. [CrossRef]

91. Eckhardt, I.; Weigert, A.; Fulda, S. Identification of IRF1 as critical dual regulator of Smac mimetic-induced apoptosis and inflammatory cytokine response. *Cell Death Dis.* 2014, 5, e1562. [CrossRef] [PubMed]

92. Beug, S.T.; Korneluk, R.G.; LaCasse, E.C. Sp3-specificity of TNF-alpha expression promotes the Smac mimetic-mediated killing of cancer cells. *Mol. Cell Oncol.* 2019, 6, 1607456. [CrossRef] [PubMed]

93. Beug, S.T.; Cheung, H.H.; Sanda, T.; St-Jean, M.; Beauregard, C.E.; Mamady, H.; Baird, S.D.; LaCasse, E.C.; Korneluk, R.G. The transcription factor SP3 drives TNF-α expression in response to Smac mimetics. *Sci. Signal.* 2019, 12. [CrossRef] [PubMed]

94. Crawford, N.; Stasik, I.; Holohan, C.; Majkut, J.; McGrath, M.; Johnston, P.G.; Chessari, G.; Ward, G.A.; Waugh, D.J.; Fennell, D.A.; et al. SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma. *Cell Death Dis.* 2013, 4, e733. [CrossRef] [PubMed]

95. Beug, H.H.; Mahoney, D.J.; Lacasse, E.C.; Korneluk, R.G. Down-regulation of c-FLIP enhances death of cancer cells by smac mimetic compound. *Cancer Res.* 2009, 69, 7729–7738. [CrossRef] [PubMed]

96. Cong, H.; Xu, L.; Wu, Y.; Qu, Z.; Bian, T.; Zhang, W.; Xing, C.; Zhuang, C. Inhibitor of apoptosis protein (IAP) antagonists in anticancer agent discovery: Current status and perspectives. *J. Med. Chem.* 2019, 62, 5750–5772. [CrossRef]

97. Zhu, H.; Li, Y.; Liu, Y.; Han, B. Bivalent SMAC mimetics for treating cancer by antagonizing inhibitor of apoptosis proteins. *ChemMedChem* 2019, 14, 1951–1962. [CrossRef]

98. Fulda, S.; Wick, W.; Weller, M.; Debatin, K.-M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. *Nat. Med.* 2002, 8, 808–815. [CrossRef] [PubMed]

99. Arnt, C.R.; Chiorean, M.V.; Heldebrant, M.P.; Gores, G.J.; Kaufmann, S.H. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. *J. Biol. Chem.* 2002, 277, 44236–44243. [CrossRef]

100. Yang, L.; Mashima, T.; Sato, S.; Mochizuki, M.; Sakamoto, H.; Yamori, T.; Oh-Hara, T.; Tsuruo, T. Predominant suppression of apoptosis by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: Therapeutic effect of a novel polyarginine-conjugated Smac peptide. *Cancer Res.* 2003, 63, 831–837.

101. Oost, T.K.; Sun, C.; Armstrong, R.C.; Al-Assaad, A.-S.; Betz, S.F.; Deckwerth, T.L.; Ding, H.; Elmore, S.W.; Meadows, R.P.; Olejniczak, E.T.; et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. *J. Med. Chem.* 2004, 47, 4417–4426. [CrossRef] [PubMed]

102. Li, L.; Thomas, R.M.; Suzuki, H.; De Brabander, J.K.; Wang, X.; Harran, P.G. A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. *Science* 2004, 305, 1471–1474. [CrossRef]

103. Sun, H.; Nikolovska-Coleska, Z.; Lu, J.; Qiu, S.; Yang, C.Y.; Gao, W.; Meagher, J.; Stuckey, J.; Wang, S. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria-derived activator of caspase (Smac) mimic. *J. Med. Chem.* 2006, 49, 7916–7920. [CrossRef] [PubMed]

104. Zhang, B.; Nikolovska-Coleska, Z.; Zhang, Y.; Bai, L.; Qiu, S.; Yang, C.Y.; Sun, H.; Wang, S.; Wu, Y. Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases. *J. Med. Chem.* 2008, 51, 7352–7355. [CrossRef] [PubMed]

105. Sun, H.; Stuckey, J.A.; Nikolovska-Coleska, Z.; Qin, D.; Meagher, J.L.; Qiu, S.; Lu, J.; Yang, C.Y.; Saito, N.G.; Wang, S. Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). *J. Med. Chem.* 2008, 51, 7169–7180. [CrossRef]
Cells 2020, 9, 1012

106. Sun, H.; Lu, J.; Liu, L.; Yi, H.; Qiu, S.; Yang, C.-Y.; Deschamps, J.R.; Wang, S. Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. *J. Med. Chem.* 2010, 53, 6361–6367. [CrossRef]

107. Bellail, A.C.; Qi, L.; Mulligan, P.; Chhabra, V.; Hao, C. TRAIL agonists on clinical trials for cancer therapy: The promises and the challenges. *Rev. Recent Clin. Trials* 2009, 4, 34–41. [CrossRef]

108. Fakler, M.; Loeder, S.; Vogler, M.; Schneider, K.; Jeremias, I.; Debatin, K.-M.; Fulda, S. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. *Blood* 2009, 113, 1710–1722. [CrossRef]

109. Vogler, M.; Walczak, H.; Stadel, D.; Haas, T.L.; Genze, F.; Jovanovic, M.; Gschwend, J.E.; Simmet, T.; Debatin, K.-M.; Fulda, S. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. *Cancer Res.* 2008, 68, 7956–7965. [CrossRef]

110. Loeder, S.; Drensek, A.; Jeremias, I.; Debatin, K.-M.; Fulda, S. Small molecule XIAP inhibitors sensititize childhood acute leukemia cells for CD95-induced apoptosis. *Int. J. Cancer* 2010, 126, 2216–2228. [CrossRef]

111. Fingas, C.D.; Blehaccz, B.R.; Smoot, R.L.; Guicciardi, M.E.; Mott, J.; Bronk, S.F.; Werneburg, N.W.; Sirica, A.E.; Gores, G.J. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. *Hepatology* 2010, 52, 550–561. [CrossRef]

112. Lu, J.; McEachern, D.; Sun, H.; Bai, L.; Peng, Y.; Qiu, S.; Miller, R.; Liao, J.; Yi, H.; Liu, M.; et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. *Mol. Cancer Ther.* 2011, 10, 902–914. [CrossRef] [PubMed]

113. Bockbrader, K.M.; Tan, M.; Sun, Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. *Oncogene* 2005, 24, 7381–7388. [CrossRef] [PubMed]

114. Krepler, C.; Chunduru, S.K.; Halloran, M.B.; He, X.; Xiao, M.; Vultur, A.; Villanueva, J.; Mitsuuchi, Y.; Neiman, E.M.; Benetatos, C.; et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. *Clin. Cancer Res.* 2013, 19, 1784–1794. [CrossRef] [PubMed]

115. Vanlangenakker, N.; Vanden Berghe, T.; Bogaert, P.; Laukens, B.; Zobel, K.; Deshayes, K.; Vucic, D.; Fulda, S.; Vandenameele, P.; Bertrand, M.J.M. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. *Cell Death Differ.* 2011, 18, 656–665. [CrossRef] [PubMed]

116. He, G.W.; Gunther, C.; Thonn, V.; Yu, Y.Q.; Martini, E.; Buchen, B.; Neurath, M.F.; Sturzl, M.; Becker, C. Regression of apoptosis-resistant colorectal tumors by induction of necroptosis in mice. *J. Exp. Med.* 2017, 214, 1655–1662. [CrossRef]

117. Li, B.X.; Wang, H.B.; Qiu, M.Z.; Luo, Q.Y.; Yi, H.J.; Yan, X.L.; Pan, W.T.; Yuan, L.P.; Zhang, YX.; Xu, J.H.; et al. Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway. *J. Exp. Clin. Cancer Res.* 2018, 37, 53. [CrossRef]

118. Foster, F.M.; Owens, T.W.; Tannianis-Hughes, J.; Clarke, R.B.; Brennan, K.; Bundred, N.J.; Streuli, C.H. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. *Breast Cancer Res.* 2009, 11, R41. [CrossRef]

119. Majorini, M.T.; Manenti, G.; Mano, M.; De Cecco, L.; Conti, A.; Pinciroti, P.; Fontanella, E.; Tagliabue, E.; Chiiodoni, C.; Colombo, M.P.; et al. cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells. *Cell Death Differ.* 2018, 25, 2147–2164. [CrossRef]

120. Ziegler, D.S.; Wright, R.D.; Kesari, S.; Lemieux, M.E.; Tran, M.A.; Jain, M.; Zawel, L.; Kung, A.L. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. *J. Clin. Investig.* 2008, 118, 3109–3122. [CrossRef]

121. Lecis, D.; Drago, C.; Manzoni, L.; Seneci, P.; Scolastico, C.; Mastrangelo, E.; Bolognesi, M.; Anichini, A.; Kashkar, H.; Walczak, H.; et al. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. *Br. J. Cancer* 2010, 102, 1707–1716. [CrossRef] [PubMed]

122. Dineen, S.P.; Roland, C.L.; Greer, R.; Carbon, J.G.; Toombs, J.E.; Gupta, P.; Bardeesy, N.; Sun, H.; Williams, N.; Minna, J.D.; et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. *Cancer Res.* 2010, 70, 2852–2861. [CrossRef] [PubMed]

123. Greer, R.M.; Peyton, M.; Larsen, J.E.; Girard, L.; Xie, Y.; Gazdar, A.F.; Harran, P.; Wang, L.; Brekken, R.A.; Wang, X.; et al. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-alpha-independent manner. *Cancer Res.* 2011, 71, 7640–7648. [CrossRef] [PubMed]
124. Sun, Q.; Zheng, X.; Zhang, L.; Yu, J. Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway. Clin. Cancer Res. 2011, 17, 2361–2372. [CrossRef]

125. Petrucci, E.; Pasquini, L.; Bernabei, M.; Saule, E.; Biffoni, M.; Accarino, F.; Sibio, S.; Di Giorgio, A.; Di Donato, V.; Casorelli, A.; et al. A small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells. PLoS ONE 2012, 7, e35073. [CrossRef]

126. Bhatti, I.A.; Abhari, B.A.; Fulda, S. Identification of a synergistic combination of Smac mimetic and Bortezomib to trigger cell death in B-cell non-Hodgkin lymphoma cells. Cancer Lett. 2017, 405, 63–72. [CrossRef]

127. Zhao, L.; Yang, G.; Bai, H.; Zhang, M.; Mou, D. NCTD promotes Birinapant-mediated anticancer activity in CRC cells for gamma-irradiation-induced apoptosis. Mol. Cancer Ther. 2014, 13, 867–879. [CrossRef] [PubMed]

128. Frommann, K.; Appl, B.; Hundsdoerfer, P.; Reinhagen, K.; Eschenburg, G. Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment. J. Pediatr. Surg. 2018, 53, 2059–2064. [CrossRef]

129. Thibault, B.; Genre, L.; Le Naour, A.; Broca, C.; Mery, E.; Vuagniaux, G.; Delord, J.P.; Wiedemann, N.; Couderc, B. DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death. Sci. Rep. 2018, 8, 17862. [CrossRef]

130. Zhou, B.; Zhang, J.; Chen, G.; You, L.; Zhang, T.P.; Zhao, Y.P. Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer. Cancer Lett. 2013, 329, 118–124. [CrossRef]

131. Benetatos, C.A.; Mitsuuchi, Y.; Burns, J.M.; Neiman, E.M.; Condon, S.M.; Yu, G.; Seipel, M.E.; Kapoor, G.S.; Laporte, M.G.; Rippin, S.R.; et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-kappaB activation, and is active in patient-derived xenograft models. Mol. Cancer Ther. 2014, 13, 867–879. [CrossRef] [PubMed]

132. Langdon, C.G.; Wiedemann, N.; Held, M.A.; Mamillapalli, R.; Iyidogan, P.; Theodosakis, N.; Platt, J.T.; Levy, F.; Vuagniaux, G.; Wang, S.; et al. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells. Oncotarget 2015, 6, 37410–37425. [CrossRef] [PubMed]

133. Runckel, K.; Barth, M.J.; Mavis, C.; Gu, J.J.; Hernandez-Illaliturri, F.J. The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma. Blood Adv. 2018, 2, 3516–3525. [CrossRef] [PubMed]

134. Shekhar, T.M.; Burvenich, I.J.G.; Harris, M.A.; Rigopoulos, A.; Zanker, D.; Spurling, A.; Parker, B.S.; Walkley, C.R.; Scott, A.M.; Hawkins, C.J. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice. BMC Cancer 2019, 19, 924. [CrossRef] [PubMed]

135. Huerta, S.; Gao, X.; Livingston, E.H.; Kapur, P.; Sun, H.; Anthony, T. In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201. Surgery 2010, 148, 346–353. [CrossRef] [PubMed]

136. Langdon, C.G.; Wiedemann, N.; Held, M.A.; Mamillapalli, R.; Iyidogan, P.; Theodosakis, N.; Platt, J.T.; Levy, F.; Vuagniaux, G.; Wang, S.; et al. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells. Oncotarget 2015, 6, 37410–37425. [CrossRef] [PubMed]

137. Yang, J.; McEachern, D.; Li, W.; Davis, M.A.; Li, H.; Morgan, M.A.; Bai, L.; Sebolt, J.T.; Sun, H.; Lawrence, T.S.; et al. Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases. Mol. Cancer Ther. 2011, 10, 658–669. [CrossRef]

138. Qin, Q.; Zuo, Y.; Yang, X.; Lu, J.; Zhan, L.; Xu, L.; Zhang, C.; Zhu, H.; Liu, J.; Liu, Z.; et al. Smac mimetic compound LCL161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein. Tumour Biol. 2014, 35, 2565–2574. [CrossRef]

139. Berger, R.; Jennen-Steinbach, V.; Marschall, V.; Karl, S.; Cristofanon, S.; Wagner, L.; Vellanki, S.H.; Hehlsgans, S.; Rodel, F.; Debatin, K.M.; et al. NF-kappaB is required for Smac mimetic-mediated sensitization of glioblastoma cells for gamma-irradiation-induced apoptosis. Mol. Cancer Ther. 2011, 10, 1867–1875. [CrossRef]

140. Chen, C.; Condon, S.M.; Yu, G.; Seipel, M.E.; Kapoor, G.S.; Laporte, M.G.; Rippin, S.R.; et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-kappaB activation, and is active in patient-derived xenograft models. Mol. Cancer Ther. 2014, 13, 867–879. [CrossRef] [PubMed]

141. Yang, J.; McEachern, D.; Li, W.; Davis, M.A.; Li, H.; Morgan, M.A.; Bai, L.; Sebolt, J.T.; Sun, H.; Lawrence, T.S.; et al. Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases. Mol. Cancer Ther. 2011, 10, 658–669. [CrossRef]

142. Qin, Q.; Zuo, Y.; Yang, X.; Lu, J.; Zhan, L.; Xu, L.; Zhang, C.; Zhu, H.; Liu, J.; Liu, Z.; et al. Smac mimetic compound LCL161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein. Tumour Biol. 2014, 35, 2565–2574. [CrossRef]

143. Berger, R.; Jennen-Steinbach, V.; Marschall, V.; Karl, S.; Cristofanon, S.; Wagner, L.; Vellanki, S.H.; Hehlsgans, S.; Rodel, F.; Debatin, K.M.; et al. NF-kappaB is required for Smac mimetic-mediated sensitization of glioblastoma cells for gamma-irradiation-induced apoptosis. Mol. Cancer Ther. 2011, 10, 1867–1875. [CrossRef]

144. Hehlsgans, S.; Oppermann, J.; Reichert, S.; Fulda, S.; Rodel, C.; Rodel, F. The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. Radiat. Oncol. 2015, 10, 198. [CrossRef]

145. Yang, L.; Kumar, B.; Shen, C.; Zhao, S.; Blakaj, D.; Li, T.; Romito, M.; Teknos, T.N.; Williams, T.M. LCL161, a SMAC-mimetic, preferentially radiosensitizes human papillomavirus-negative head and neck squamous cell carcinoma. Mol. Cancer. 2019, 18, 1025–1035. [CrossRef]

146. Flygare, J.A.; Beresini, M.; Budha, N.; Chan, H.; Chan, I.T.; Cheeti, S.; Cohen, F.; Deshayes, K.; Doerner, K.; Eckhardt, S.G.; et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J. Med. Chem. 2012, 55, 4101–4113. [CrossRef] [PubMed]
142. Tolcher, A.W.; Bendell, J.C.; Papadopoulos, K.P.; Burris, H.A.; Patnaik, A.; Fairbrother, W.J.; Wong, H.; Budha, N.; Darbonne, W.C.; Peale, F.; et al. A phase I dose-escalation study evaluating the safety tolerability and pharmacokinetics of CUDC-427, a potent, oral, monovalent IAP antagonist, in patients with refractory solid tumors. *Clin. Cancer Res.* 2016, 22, 4567–4573. [CrossRef] [PubMed]

143. Wong, H.; Gould, S.E.; Budha, N.; Darbonne, W.C.; Kadel, E.E.; La, H.; Alickie, B.; Halladay, J.S.; Erickson, R.; Portera, C.; et al. Learning and confirming with preclinical studies: Modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. *Drug Metab. Dispos.* 2013, 41, 2104–2113. [CrossRef] [PubMed]

144. Infante, J.R.; Dees, E.C.; Olszanski, A.J.; Dhuria, S.V.; Sen, S.; Cameron, S.; Cohen, R.B. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. *J. Clin. Oncol.* 2014, 32, 3103–3110. [CrossRef] [PubMed]

145. Cai, Q.; Sun, H.; Peng, Y.; Lu, J.; Nikolovska-Coleska, Z.; McEachern, D.; Liu, L.; Qiu, S.; Yang, C.Y.; Miller, R.; et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. *J. Med. Chem.* 2011, 54, 2714–2726. [CrossRef]

146. Hurwitz, H.I.; Smith, D.C.; Pitot, H.C.; Brill, J.M.; Chugh, R.; Rouits, E.; Rubin, J.; Strickler, J.; Vuagniaux, G.; Sorensen, J.M.; et al. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: Results of a first-in-man study. *Cancer Chemother. Pharmacol.* 2015, 75, 851–859. [CrossRef]

147. Chessari, G.; Buck, I.M.; Day, J.E.H.; Day, P.J.; Iqbal, A.; Johnson, C.N.; Lewis, E.J.; Martins, V.; Miller, D.; Reader, M.; et al. Fragment-based drug discovery targeting inhibitor of apoptosis proteins: Discovery of a non-alanine lead series with dual activity against cIAP1 and XIAP. *J. Med. Chem.* 2015, 58, 6574–6588. [CrossRef]

148. Mita, M.M.; LoRusso, P.M.; Papadopoulos, K.P.; Gordon, M.S.; Mita, A.C.; Ferraldeschi, R.; Keer, H.; Oganesian, A.; Su, X.Y.; Jueller, S.; et al. A phase 1 study of ASTX660, an antagonist of inhibitors of apoptosis proteins, in adults with advanced cancers or lymphoma. *Clin. Cancer Res.* 2020. [CrossRef]

149. Condon, S.M.; Mitsuuchi, Y.; Deng, Y.; LaPorte, M.G.; Rippin, S.R.; Haimowitz, T.; Alexander, M.D.; Kumar, P.T.; Hendi, M.S.; Lee, Y.H.; et al. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. *J. Med. Chem.* 2014, 57, 3666–3677. [CrossRef]

150. Amaravadi, R.K.; Schilder, R.J.; Martin, L.P.; Levin, M.; Graham, M.A.; Weng, D.E.; Adjei, A.A. A phase I study of the SMAC-mimetic Birinapant in adults with refractory solid tumors or lymphoma. *Mol. Cancer Ther.* 2015, 14, 2569–2575. [CrossRef]

151. Noonan, A.M.; Bunch, K.P.; Chen, J.Q.; Herrmann, M.A.; Lee, J.M.; Kohn, E.C.; O’ Sullivan, C.C.; Jordan, E.; Houston, N.; Takebe, N.; et al. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. *Cancer* 2016, 122, 588–597. [CrossRef] [PubMed]

152. Lecis, D.; Masrangelo, E.; Belvisi, L.; Bolognesi, M.; Civera, F.; De Cesare, M.; Delia, D.; Drago, C.; Manenti, G.; et al. Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization. *Bioorg. Med. Chem.* 2012, 20, 6709–6723. [CrossRef] [PubMed]

153. Li, N.; Feng, L.; Han, H.Q.; Yuan, J.; Qi, X.K.; Yia, Y.F.; Zhang, Y.C.; Deng, C.C.; Zhang, H.J.; et al. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis. *Cancer Lett.* 2016, 381, 14–22. [CrossRef] [PubMed]

154. Kipp, R.A.; Case, M.A.; Wist, A.D.; Cresson, C.M.; Carrell, M.; Griner, E.; Wiita, A.; Albiniak, P.A.; Chai, J.; Shi, Y.; et al. Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners. *Biochemistry* 2002, 41, 7344–7349. [CrossRef] [PubMed]

155. Rettinger, E.; Glatthaar, A.; Abhari, B.A.; Oelsner, S.; Pfirrmann, V.; Huenecke, S.; Kuci, S.; Kreyenberg, H.; Willasch, A.M.; Klingebiel, T.; et al. SMAC mimetic BV6 enables sensitization of resistant tumor cells but also affects cytokine-induced killer (CIK) cells: A potential challenge for combination therapy. *Front Pediatr.* 2014, 2, 75. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).